Playback speed
10 seconds
This video is featured in the 2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "PROs of the MEDISARC Study (AIO-STS-0415) - Durvalumab & Tremelimumab vs. Doxorubicin in Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Viktor Grünwald
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Viktor Grünwald
64 views
June 12, 2024
Login to view comments.
Click here to Login